1980

• First stem cell transplant in the State of Ohio performed by Dr. Hillard Lazarus at University Hospitals Case Medical Center (UHCMC).  

1986

• Drs. Arnold Caplan and Stephen Haynesworth, Department of Biology at Case Western Reserve University (CWRU), filed a series of patent applications describing mesenchymal stem cells. These stem cells patents have now become the foundation for an internationally recognized industry for cellular therapeutics.

1989-2000

• A series of patents was secured by CWRU for mesenchymal stem cell transplantation, mesenchymal gene therapy, mesenchymal support of hematopoietic stem cell transplantation, etc.

1994

• Drs. Caplan and Haynesworth founded Osiris Therapeutics, a company devoted to mesenchymal stem cell research and therapeutics.

1996-2000

• Three first-in-the-nation clinical trials began at UHCMC using mesenchymal stem cells.

1997

• Dr. Mary Laughlin performed the first adult umbilical cord transplant at UHCMC.

1999

• Dr. Stan Gerson received a patent for drug selection stem cell gene therapy. This patent led to three clinical trials, with two in Ohio: one in Cleveland and the other in Cincinnati.

2002

• The National Heart, Lung and Blood Institute and the National Cancer Institute (NHLBI/NCI) awarded UHCMC and Case Transplant Program headed by Dr. Hillard Lazarus a Stem Cell Transplantation Center of Excellence. This award entitled UHCMC and CWRU to become one of the fifteen centers nationally to participate in stem cell transplantation.

2003

• The NHLBI awarded Dr. Jaroslaw Maciejewski, Cleveland Clinic (CC), a Center of Excellence in Stem Cell Failure Syndromes.
• The Center for Stem Cell and Regenerative Medicine was established by CWRU, CC, UHCMC and Athersys, Inc. with a $19.5 million award from the State of Ohio as a Wright Center of Innovation.
• The NHLBI awarded Dr. Jaroslaw Maciejewski, CC, a Center of Excellence in Stem Cell Failure Syndromes.

2004

• Drs. Trapp, Macklin and Miller, at CC and CWRU, were awarded a National Center of Excellence in Multiple Sclerosis in Stem Cell Research.
• Arteriocyte, Inc. formed to focus on the use of stem cell technology to increase blood flow with initial focus on cardiovascular applications.
• AcelleRx spun out from CC Innovations to use molecular cues and stem cells to increase myocardial repair after myocardial infarction.
• Cell Targeting created to use transient molecular markers to direct cell homing.
• Ohio BioGel began through scaffold and tissue engineering technology for cartilage replacement and visco-supplementation.

2005

• Federal Appropriation of $4.5 million for National Center of Regenerative Medicine (NCRM). 
• Ohio Board of Regents funds $1.25 million for Ohio Eminent Scholar for Stem Cell Research. 
• Construction of CC Department of Stem Cell and Regenerative Medicine is completed. 
• FDA compliant Clinical Cell Processing Facility is opened on the Sixth Floor of the Wolstein Building.

2006

• Received an additional $8 million award from the State of Ohio.
• Initiated the Ohio Cell-Based Therapy Consortium to coordinate and pursue multi-institutional clinical trials across the State of Ohio. 
• Opened the Small Animal Imaging Center with access to world-class imaging technologies used in preclinical and clinical studies.

2007

• Held Adult Mesenchymal Stem Cells in Regenerative Medicine conference (MSC 2007), an international stem cell meeting which had over 300 attendees from 27 different countries, accepted 100 abstracts and brought together 127 different institutions from around the world.
• Collaborated with the Great Lakes Science Center to redesign their BioMedTech Exhibit. 
• With the support of the Myelin Repair Foundation, started the Human Neural Assay Center with Dr. Miller.
• Invenio Therapeutics incorporated to commercialize a new drug to treat leukemia.